Pharmafile Logo
Pharmafocus logo
Advanced Search

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024
Medical Communications FDA, Oncology, Roche, lung cancer

Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) for the adjuvant treatment following …

News

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024
Research and Development GSK, Reproductive health, clinical trial, gonorrhoea, sexual health

GSK has announced positive results from its phase 3 EAGLE-1 trial for gepotidacin, a potential first-in-class oral antibiotic for the …

News

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024
Research and Development Ear Nose & throat, Eli Lilly, clinical trial, sleep apnoea, tirzepatide

Eli Lilly has announced positive topline results from its SURMOUNT-OSA phase 3 trials which demonstrated that tizepatide injection (10mg or …

News

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024
Research and Development AbbVie, Immunology, Medincell, collaboration

Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and commercialise up to six next-generation …

News

Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

April 17, 2024
Research and Development Intra-Cellular Therapies, Neurology, clinical trial, major depressive disorder, mental health

Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as an adjunctive therapy to antidepressants …

News

Novartis shares new data about Fabhalta for IgAN treatment

April 16, 2024
Research and Development Fabhalta, IgAN, Nephrology, Novartis, nephropathy

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN trial of Fabhalta (iptacopan), an …

News

GSK’s meningococcal vaccine candidate accepted for FDA review

April 16, 2024
Medical Communications FDA, GSK, Immunology, meningococcal

GSK has announced that the US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) …

News

Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

April 15, 2024
Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of …

News

FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment

April 15, 2024
Medical Communications Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer

Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, …

News

Lipocine announces results from phase 2 trial for obesity drug

April 12, 2024
Research and Development Lipocine, Obesity, clinical trial, weight loss

Lipocine Inc has announced results from its phase 2 clinical trial (NCT04134091), which includes results for LPCN 2401, the company’s …

News

Baxter expands US portfolio with new injectables

April 12, 2024
Medical Communications Pharmacy, baxter, injectables, product launch

Baxter International has announced the continued expansion of its pharmaceuticals portfolio with the launch of five new injectable products in …

News

Vertex to acquire Alpine Immune Sciences for $4.9bn

April 11, 2024
Business Services Alpine Immune Sciences, Nephrology, Vertex pharmaceuticals, acquisition, nephropathy

Vertex Pharmaceuticals and Alpine Immune Sciences have announced that they have entered into a definitive agreement under which Vertex will …

News

NICE recommends migraine treatment for NHS use

April 11, 2024
Medical Communications NHS, NICE, Neurology, migraine

The National Institute for Health and Care Excellence (NICE) has shared draft guidance recommending AbbVie’s Aquipta (atogepant) as an option …

News

TILT Biotherapeutics shares data on TILT-123 with Keytruda for ovarian cancer treatment

April 10, 2024
Research and Development Merck, National Cancer Institute, Oncology, TILT Biotherapeutics, keytruda, ovarian cancer

TILT Biotherapeutics has announced promising preliminary safety and efficacy data from its ongoing phase 1 clinical trial (NCT05271318) in platinum …

News

FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment

April 10, 2024
Research and Development FDA, Oncology, Oryzon, lung cancer

Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its investigational new drug (IND) application …

News

An overview of women’s health in 2024

April 9, 2024
Reproductive health, abortion, fertility, reproductive health, women's health

Betsy Goodfellow from Pharmafocus considers the current landscape of women’s health, covering recent debates and ongoing issues within the reproductive health sphere …

Feature

Gilead’s Veklury recommended by NICE for COVID-19 treatment

April 9, 2024
Medical Communications COVID-19, Gilead Sciences, Infections and infestations, remdesivir

Gilead Sciences has announced that the National Institute of Health and Care Excellence (NICE) has recommended the use of Veklury …

News

PureTech Health launches Seaport Therapeutics

April 9, 2024
Business Services Financing, Neurology, PureTech Health, launch

PureTech Health has announced key progress on its ‘strategic initiatives to deliver innovative medicines to patients and unlock value for …

News

Geneos Therapeutics shares data from phase 1/2 trial for cancer vaccine

April 8, 2024
Research and Development Cancer, Geneos Therapeutics, Oncology, clinical trial

Geneos Therapeutics has announced that it has published positive safety, immunogenicity and efficacy data from the full cohort of patients …

News

Johnson & Johnson to acquire Shockwave Medical

April 8, 2024
Business Services Cardiology, Johnson & Johnson, Shockwave Medical, acquisition

Johnson & Johnson (J&J) and Shockwave Medical have announced that they have entered into a definitive agreement under which J&J …

News

AstraZeneca shares results for Imfinzi in phase 3 trial for small cell lung cancer

April 5, 2024
Research and Development AstraZeneca, Imfinzi, Oncology, clinical trial, lung cancer

AstraZeneca has announced positive high-level results from the phase 3 ADRIATIC trial, which demonstrated that Imfinzi (durvalumab) had a statistically …

News

Latest content

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024

Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy

April 17, 2024